Bayer's New CEO Outlines Sweeping Restructuring Plan to Boost Share Price

SmartCom Finance APP learned from an informed source that the newly appointed CEO of Bayer, a giant in Germany's healthcare industry, plans to significantly cut management positions to expedite decision-making and operational efficiency. This marks the first step in overhauling the troubled German industrial group, which is now also under immense pressure from investors demanding a spin-off. According to the source, Bill Anderson, who has been at the helm since June, is eager to demonstrate to investors the company’s rapid pace of improvement while buying himself more time to formulate a broader, comprehensive restructuring plan in the coming months.

One of the sources said that Anderson plans to present the initial layoff plan at an upcoming strategic meeting within the company, while another source said that these measures will affect middle and upper-level managers, resulting in a yet-to-be-determined amount for the one-time "severance package" for departing employees. The number of jobs affected and the timing of the announcement remain unclear. A Bayer spokesperson declined to comment.

Former Roche executive Anderson told analysts after the release of the second-quarter results that too much red tape, combined with the company's debt and lawsuits related to the herbicide Roundup and the chemical PCB, meant the company was missing out on development opportunities. "Pending litigation, corporate bureaucracy, and debt levels are all impacting our ability to focus on our mission," he said at an August meeting.

He added at the time that he would change the annual budget cycle to a 90-day budget cycle and allow teams closely connected with customers to make business decisions, rather than having these decisions made by upper management.

Market concerns remain

Anderson's appointment has been widely welcomed by the company's shareholders and is considered the most qualified CEO candidate to comprehensively reform Bayer. He will replace his predecessor, Werner Baumann, who was criticized for not responding promptly to concerns in the capital markets.

But the new CEO may have only a short breather to come up with concrete strategic recommendations. Last month, investment firm Artisan Partners stated that the company needs to separate all three of its major businesses — agriculture, prescription drugs, and consumer health products.

Activist investor Bluebell Capital Partners called for a split earlier this year. Other major institutional investors, including mutual fund group Deka, have expressed dissatisfaction with the company's previous leadership. Some investors suggested that a simple solution would be to separate the healthcare and agriculture businesses.

One of Anderson's key tasks is to revitalize Bayer's stock price. Lingering costs from U.S. herbicide litigation and the company’s delayed response to capital market concerns have caused Bayer’s stock performance to lag far behind its competitors. So far this year, Bayer’s stock has risen by only 6%, while its peer Novartis has surged by 18%.

Anderson said last month that he was "leaving no stone unturned" in his review of the company's strategy and structure, and would not rule out any options. He added that he would provide an initial update in the coming months, with a more detailed plan to follow in early 2024.

The company said in a provisional statement last month that it expected its profitability to decline further and that its free cash flow might be zero. Some analysts believe Anderson is trying to release bad news all at once quickly so as to replan various businesses.